Melanotan II (MT-II)

Phase 2Small molecule

HHudson Biotech

Melanotan II (MT-II) is one of 28 small molecule programs targeting Vitiligo. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VitiligoRecruiting

VitiligoPhase 2

Recruiting

Competition

Competitive Landscape

34 competitors in Vitiligo

#DrugCompanyPhaseTrials

Jakafi

Incyte

Approved

8 2

Trexall

Jazz Pharmaceuticals

Approved

2 3

Cosentyx

Novartis

Approved

1 4

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

2 5

Decadron

AAspen Global Incorporated

Approved

2 6

Asmanex

PPerrigo Company

Approved

1 7

Elidel

BBausch Health Americas, Inc.

Adrucil

Rapamune

PPrism Pharmaceuticals

Rinvoq

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Vitiligo

NCT07437560

Clinical

Trials by Indication[1]

Vitiligo1 trial

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

Recruiting·HHudson Biotech·Phase 2·NCT07437560·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melanotan II (MT-II). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melanotan II (MT-II) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melanotan II (MT-II). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hudson Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHudson Biotech

Melanotan II (MT-II)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Vitiligo1 trial

References

Drug Info

Quick Facts

Related News